Veradermics, Incorporated

NYSE: MANE · Healthcare · Biotechnology

PublicHQ New Haven, CT · New HavenCIK 0001827635Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH 68DQ —GM —SS 47

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$70.0M

Employees

as of 2026-09-07

Market cap

$4.1B

as of 2026-09-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$70.0M-$70.0M2025

Operating income-$72.3M-$72.3M2025

Total assets$152.6M$152.6M2025

Liabilities$9.2M$9.2M2025

Equity-$121.0M-$121.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Veradermics, Incorporated’s financial profile?

Veradermics, Incorporated earned -$70.0M in FY2025 net income.

Peers · Healthcare

Edgewise Therapeutics, Inc.——Dyne Therapeutics, Inc.——Enliven Therapeutics, Inc.——Legend Biotech Corporation——Galera Therapeutics, Inc.——Vicore Pharma Holding AB——

Neighbors

New Haven →

Trevi Therapeutics, Inc.——Biohaven Ltd.——Arvinas, Inc.$262.6M61C Rallybio Corporation$858.0k47D Precipio, Inc.$24.2M69B Pegasus Tel, Inc.——

Key facts

CEOReid Waldman

SectorHealthcare

IndustryBiotechnology

HeadquartersNew Haven, CT

ExchangeNYSE: MANE

Employees37

IPO date2026-02-04

Latest filings

10-Q2026-08-11 8-K2026-08-11 8-K2026-07-15 10-Q2026-05-12 8-K2026-05-12 8-K2026-05-01 8-K2026-04-27 8-K2026-04-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.